Omega-3 Index is Directly Associated with a Healthy Red Blood Cell Distribution Width

Michael I. McBurney[1-3], Nathan L. Tintle[1,4], and William S. Harris[1,5]

[1]Fatty Acid Research Institute, Sioux Falls, SD 57106, USA (MIM, NLT, WSH); [2]Department of

Human Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada

(MIM), [3]Division of Biochemical and Molecular Biology, Friedman School of Nutrition Science

and Policy, Tufts University, Boston, MA 02111, USA (MIM); [4]Department of Population Health

Nursing Science, College of Nursing, University of Illinois – Chicago, Chicago, IL 60612,

USA(NLT); [5]Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA

(WSH).

Authors' last names: McBurney, Tintle, Harris

Corresponding author: M.I. McBurney, Department of Human Health & Nutritional Sciences,

University of Guelph, Guelph, ON N1G 2W1, Canada. E-mail: mim@faresinst.com

Reprint requests: W.S. Harris, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail:

wsh@faresinst.com

Sources of Support: This work was supported by the Fatty Acid Research Institute (FARI). FARI is

a non-profit foundation bringing together nutrition scientists and biostatistical experts to

accelerate discovery of the relationships between fatty acids, especially omega-3 fatty acids,

and health. Pending application and approval, data described in the manuscript, code book, and

analytic code will be made available upon request to the Fatty Acid Research Institute

(https://www.faresinst.org/).

Abbreviations: BMI, body mass index; CRP, high-sensitivity C-reactive protein; CV, coefficient of

variation; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Hb, hemoglobin; MCV,

mean corpuscular volume; O3I, omega-3 index; RBC, red blood cells. RDW, red blood cell

distribution width; SD, standard deviation.

Summary

Low red blood cell (RBC) membrane content of EPA and DHA, i.e., the omega-3 index (O3I),

and elevated RBC distribution width (RDW) are risk factors for all-cause mortality. O3I and RDW

are related with membrane fluidity and deformability. Our objective was to determine if there

is a relationship between O3I and RDW in healthy adults. Subjects without inflammation or

anemia, and with values for O3I, RDW, high-sensitivity C-reactive protein (CRP), body mass

index (BMI), age and sex were identified (n=25,485) from a clinical laboratory dataset of

>45,000 individuals. RDW was inversely associated with O3I in both sexes before and after

(both p<0.00001) adjusting models for sex, age, BMI and CRP. Stratification by sex revealed a

sex-O3I interaction with the RDW-O3I slope (p<0.00066) being especially steep in females with

O3I ≤5.6%. In healthy adults of both sexes, the data suggested that an O3I of >5.6% may help

maintain normal RBC structural and functional integrity.

Keywords: hematology, red blood cells, omega-3 index, eicosapentaenoic acid,

docosahexaenoic acid

1. Introduction

Mean red blood cell (RBC) corpuscular volume (MCV) and reticulocyte count were the

principal metrics traditionally used to identify anemic disorders until the advent of automated

blood cell analyzers that could routinely measure the types and distribution of blood cells.

Among these metrics is the RBC distribution width (RDW) [1] which reflects RBC size

heterogeneity. High RDW values are associated with decreased deformability [2] and RDW is

used to diagnose sickle cell [3] and nutritional anemias (iron, folic acid and vitamin B12) [1,4,5].

In recent years, RDW has been found to be a predictor of multiple adverse health outcomes

unrelated to anemia, including increased risk for death from cardiovascular disease [6–12],

SARS-CoV-2 [13–15], sepsis [16,17], lung disease [18], and cancer [19,20].

Like all cell membranes, RBC membranes are a complex lipid bilayer [21]. Fatty acids

esterified in phospholipids contribute to the structural integrity and function of cell

membranes. In particular, the membrane content of omega-3 fatty acids, EPA and DHA, the

sum of which is called the omega-3 index (O3I) [22], increases with omega-3 fatty acid intake

[23,24] and affects cell deformability [25–28]. The O3I is a stable biomarker of long term EPA

and DHA intake [24,29]. Since both a low O3I [30] and an elevated RDW [7,31,32] are known to

be associated with risk for earlier all-cause mortality (**Supplemental Table 1**), the aim of this

cross-sectional analysis was to determine if there was an inverse relationship between the O3I

and RDW in healthy adults without evidence of inflammation or tissue injury. If there was, then

the former may play a role in maintaining a healthy distribution of RBC sizes in adults.

Furthermore, such a relationship could support the identification of a target or healthy O3I. By

establishing a nutrient: structure-function relationship in healthy individuals, these data could

be used as the basis for establishing a Dietary Reference Intake (DRI) for the long-chain omega-

3 fatty acids, i.e., EPA+DHA.

2. Patients and Methods

This was a cross-sectional analysis of data from blood samples submitted for testing to

Health Diagnostic Laboratory, Inc (HDL, Inc., Richmond VA) as part of routine clinical

assessment between 2011-2012. Data on RBC structural characteristics, i.e., MCV and RDW,

along with hemoglobin (Hb), high-sensitivity C-reactive protein (CRP), arachidonic acid (AA),

EPA, DHA, and O3I were extracted from 45,715 adults (≥18 years) without any linked patient

identifiers except age, sex and BMI (**Supplemental Table 2**). Next, 598 individuals with extreme

O3I values (i.e., <2.15 and >11.5%, the upper and lower 0.5 percentiles of the cohort), were

excluded (n=45,257). Since inflammation affects erythropoiesis, modulates RBC life span, and

increases RDW [33], 14,329 individuals with chronic inflammation (CRP >3mg/L) [34–38] were

excluded. Similarly, anemia also increases RDW [1,39], and so individuals with MCV >100 fL and

low Hb (Hb <13 g/dL for men and Hb <12 g/dL for women [40] were also excluded (**Figure 1**).

This resulted in a final, analytical dataset of 25,485 individuals (49.7% female) without

laboratory evidence of anemia or active infection, tissue injury, or inflammation (**Table 1**).

2.1 Laboratory methods

Blood samples were drawn after an overnight fast and shipped with cold packs to HDL, Inc.

for analysis with a Beckman-Coulter DxH 800 hematology analyzer (Brea, CA, USA). Samples

were prepared at each clinical site according to standardized instructions as previously

described [41]. RDW is the SD of the RBC volume divided by the MCV multiplied by 100 [39].

88 For fatty acid analysis, RBCs were separated from plasma by centrifugation and analyzed using

89 gas chromatography as previously described [42]. The University of South Dakota Institutional

90 Review Board reviewed and approved the analysis of deidentified HLD, Inc. laboratory data

91 (IRB-21-147).

92 *2.2 Statistical methods*

93  Sample characteristics were summarized using standard statistical methods (e.g., means,

94 SDs, correlations) with t-tests or adjusted linear models used to compare characteristics of male

95 and female participants above and below O3I values that were ultimately identified as primary

96 cut points in the RDW-O3I curves (see below). Splines were fit using 3rd degree polynomials

97 with knots at each decile in R (version 3.6.2; splines package). Unadjusted models used a linear

98 model to predict RDW values by splines of O3I. Adjusted models accounted for sex, age, BMI

99 and CRP values in the linear models accounting for potential non-linear relationships using

100 splines.

101  In order to identify significant changes in the shape of the RDW-O3I relationship, we used a

102 "sliding O3I window" approach. The width of each window was three O3I percentage points

103 (e.g., 3% to 6%). By moving the window up by 0.1% increments and repeatedly testing for

104 significant differences between the mean RDW in the lower vs. the upper half of the window,

105 we sought to discover O3I cut points where the RDW-O3I relationship appeared to flatten.

106 These would be O3I values above which the "effect" of an increase in O3I on RDW had little

107 impact. We began with a window midpoint of O3I =2.6%, and we used adjusted linear models in

108 R to test for upper vs lower half differences. We identified the first window which did not have

109 a statistically significant difference in upper and lower mean RDW values. The midpoint of this

window was chosen as the O3I cut point to be used in further analysis. To evaluate the

potential moderating effect of sex on the O3I relationship with RDW, MCV, Hb, CRP, BMI and

age, we inserted an interaction term into the relevant, adjusted model. Pearson correlations

were used to assess strength and direction of linear association between covariates and RDW.

Statistical significance was set to 0.05 for all analyses and 95% confidence bands are provided

where appropriate.

3. Results

The final dataset included 25,485 individuals (**Figure 1**) without acute inflammation or

anemia. Mean BMI, O3I, MCV, Hb, and CRP values differed significantly between males and

females in adjusted models (**Table 1**). RDW was significantly (p<0.00001) and inversely

associated with O3I in unadjusted (**Figure 2A**) and adjusted models (p<0.00001) (**Figure 2B**).

Independently, EPA and DHA had similar 'hockey stick' RDW-fatty acid relationships with the

bases of the curves being ~3% and ~7.3%, respectively (**Supplemental Figure 2**). RDW was not

significantly related with AA (**Supplemental Figure 2,** r=0.06). Pearson correlations (r) with RDW

were r=0.21 (age), r=0.11 (CRP), r=0.14 (BMI), r=-0.25 (MCV), and r=-0.12 (Hb). The O3I cut

point determined in the sliding window analysis, i.e. when the lower and upper half of an "O3I

sliding window" yielded mean RDW values that did not significantly differ, was 5.6% (**Figure 2B**).

That is, below an O3I of 5.6%, the curve was clearly steeper than it was above 5.6%. Because of

significant sex differences in RDW and O3I in the adjusted model (**Table 1**), and because of the

clear differences in the shapes of the RDW-O3I relationship between men and women **(Figure**

2), we stratified by sex and by O3I (≤5.6% vs >5.6%) (**Table 2**). Within sex comparisons found

significant differences between individuals with O3I ≤5.6% vs. >5.6% for all variables in the

adjusted model for females and males (**Table 2**). We observed a significant sex by O3I

interaction in the adjusted model for RDW and BMI for both sexes with the difference in RDW

below 5.6% being larger in females than males. Across all O3I concentrations, RDW continued

to decrease with increasing O3I in females whereas there was a plateauing in males, and even a

modest increase in RDW as O3I exceeded 8% (**Figure 3**).

4.   Discussion and Conclusions

RBCs are by far the most common cell in the body (83%), and as such, they have recently

been viewed as a separate organ deeply involved with homeostasis [43]. Their primary role is to

transport oxygen and carbon dioxide, and to accomplish this RBCs must pass through capillaries

whose diameter is half of their own [44]. Thus, RBCs must be highly flexible and able to

withstand high-shear stress. Here, we report an inverse relationship between the percentage of

omega-3 fatty acids in RBC membranes and the distribution of RBC sizes in a generally healthy

(i.e., not anemic and without inflammation) cohort (**Figure 2**), as well as an interaction with sex

(**Figure 3**). In both males and females, RDW was observed to be increasing with decreasing O3I

below 5.6% (**Figure 2; Table 2**). The direction of the O3I-RDW relationship changed in males

with O3I >~8% but the increase in RDW is unlikely to have clinical significance.

Changes in saturated and unsaturated fatty acid composition in cell membranes affect

membrane fluidity [45–47] and deformability [28,48]. EPA and DHA have specific biophysical

properties that affect the properties of membranes enriched in them [49]. Among these

properties are fluidity, deformability, and susceptibility to aggregation of RBCs [26,28].

Increases in membrane DHA (a highly flexible molecule) influence the flexibility and structural

integrity, i.e. lipid-protein interactions, of RBC membranes [50]. Increasing EPA intake alone or

EPA+DHA together increases RBC membrane fluidity [48] and RBC deformability [25–27,51].

RBC deformability is affected by membrane lipid composition and lipid-protein interactions, and

reduced deformability is a characteristic of aged RBCs [52]. Since an elevated RDW is likewise

associated with decreased RBC membrane flexibility [2], one possible explanation for our

findings is that a reduced EPA+DHA content of RBC membranes is causing the elevation in RDW.

An elevated RDW can also be caused by disordered erythropoiesis and/or RBC clearance

[53]. A delay in clearance allows smaller RBCs to continue circulating, increasing the average

age (lifespan) of RBC, and contributes to increased RDW [2]. Oxidative stress is a characteristic

of aging, malnutrition, inflammation, and the pathogenesis of chronic disease [54]. Oxidative

stress changes cytoskeletal arrangement and contributes to lipid asymmetry, causing

erythrocytes lose flexibility and RDW to increase [55]. A systematic review and meta-analysis of

39 clinical trials (2,875 participants) found omega-3 supplementation improved antioxidant

stability by significantly increasing serum total antioxidant capacity and decreasing serum

glutathione peroxidase and malondialdehyde concentrations [56]. This represents another

means by which omega-3 fatty acids could improve the RDW.

Alternatively, there may be a connection between omega-3, inflammation and the RDW.

Inflammation marked by elevated CRP, interleukin-6, etc. can suppress RBC maturation in bone

marrow, and larger immature RBCs, i.e. reticulocytes, enter the circulation and increase the

RDW [16]. This relationship between RDW and inflammation may partially explain the

relationship of higher RDW with risk of cardiovascular disease and mortality

[10,11,14,30,32,57]. Similarly, lower omega-3 fatty acid levels are associated with a heightened

inflammatory state [58–60], and omega-3 supplementation lowers inflammatory mediators

[61]. Thus, a possible explanation of our findings may be that higher omega-3 fatty acid levels

(O3I >5.6%) lower inflammatory markers which thereby lowers the RDW. Because it has been

recommended that a DRI be established for EPA+DHA [62–65], the RDW-O3I analysis was

purposefully constrained to healthy individuals with an objective of establishing a nutrient

(EPA+DHA) structure-function (RDW) relationship. When the 14,239 individuals with

inflammation (CRP >3 mg/L) were also included in the adjusted and unadjusted models, a

similar inverse RDW-O3I relationship was determined (**Supplemental Figure 2**).

Because of its cross-sectional nature, we cannot draw causal inferences from these data.

However, there is evidence that raising RBC membrane omega-3 content can improve RDW. In

patients with sickle cell disease, RBC rheological disturbances, hemolysis, and abnormalities of

membrane fatty acids, have been ameliorated by omega-3 fatty acid treatment [66,67].

Supplementation with both EPA alone or EPA+DHA lowered RDW values in patients with

coronary heart disease [51,68] and with abdominal aortic aneurysm [69]. In the latter study,

supplementation increased O3I from ~4.5% to 8% and decreased RDW from 14.8% to 13.8%.

So, one of the mechanisms underlying the health benefits of EPA and DHA could be via an

improved RDW.

The primary strength of this study was its large sample size which enabled us to explore

RDW and O3I relationships in healthy individuals (males and females separately) free of

laboratory signs of anemia or inflammation, i.e., a population suitable for the establishment of

a DRI. The most obvious limitations of this study, besides its cross-sectional nature, was the lack

of information on confounding metabolic events, dietary behaviors, medications, other medical

conditions and/or physical activities that might have also been associated with O3I and with

RDW. Another potential limitation is that these data were drawn from a clinical laboratory

database, not a formal national survey, so the representativeness of these patients to healthy

US adults is not clear. However, previous studies in this specific cohort found that standard risk

biomarkers (cholesterol, glucose, etc.) generally reflected those of typical adults living in the

United States examined in Nutrition And Health Examination Surveys (NHANES) [70]. Also, O3I

values were similar to those from a representative US sample [71], and RDW, MCV, and Hb

were within normal ranges [7,72,73]. These considerations suggest this cohort was generally

representative of the US population. The mean serum EPA+DHA concentration for adults 20+

years from NHANES was 2% [71] which is equivalent to an O3I of about 4.8%. Hence, roughly

half of Americans have an O3I <5%, i.e., the range where higher RDW may be more common.

In conclusion, low O3I levels (≤5.6%) were associated with a potentially unhealthy

distribution of RBC cell sizes. This suggests a role for EPA+DHA in maintaining RBC structure in

healthy individuals. We propose that achieving an O3I >5.6% could help maintain a normal RBC

size distribution. Our finding complements evidence that a higher O3I is linearly and inversely

associated with risk for death from any cause [30], with values of >8% characterizing the lowest

risk population [74]. Numerous researchers have called for the establishment of Dietary

Reference Intake (DRI) for EPA+DHA [63–65]. To that end, our observations that maintaining an

RBC EPA+DHA percentage above 5.6% may help maintain a normal RDW, could provide the

scientific basis for a DRI.

Disclosures: M.I. McBurney serves on the Board of Directors of the American Society for

Nutrition and has or has held consulting agreements in the past 3 years with Council for

Responsible Nutrition; Church & Dwight; DSM Nutritional Products; International Life Sciences

Institute, North America; McCormick; OmegaQuant Analytics; PepsiCo; and VitaMe

Technologies. W.S. Harris holds an interest in OmegaQuant Analytics, a lab that offers omega-3

blood testing; and is a member of the RB Schiff Science and Innovation Advisory Board. N.L.

Tintle has no conflicts to disclose.

Funding: This work was supported by the Fatty Acid Research Institute (FARI). FARI is a non-

profit foundation bringing together nutrition scientists and biostatistical experts to accelerate

discovery of the relationships between fatty acids, especially omega-3 fatty acids, and health.

CReditT authorship contribution statement: M.I. McBurney: Conceptualization & analytical

design, Writing - original draft, Writing - review & editing. **W.S. Harris**: Conceptualization &

analytical design, Funding - acquisition, Writing- review & editing. **N.L. Tintle**: Formal analysis,

Writing - review & editing.

Acknowledgements: The authors wish to thank Dr. Patrick Moriarty, Department of Internal

Medicine, Kansas University Medical Center, Kansas City, KS for the initial suggestion to explore

the relationship between omega-3 status and RDW. We also are indebted to Steven Varvel, PhD

for his help in acquiring and collating the dataset used in this study.

References

[1]   J.D. Bessman, P.R. Gilmer, F.H. Gardner, Improved Classification of Anemias by MCV and RDW, Am J Clin Pathol. 80 (1983) 322–326. https://doi.org/10.1093/ajcp/80.3.322.

[2]   K.V. Patel, J.G. Mohanty, B. Kanapuru, C. Hesdorffer, W.B. Ershler, J.M. Rifkind, Association of the Red Cell Distribution Width with Red Blood Cell Deformability, in: W.J. Welch, F. Palm, D.F. Bruley, D.K. Harrison (Eds.), Oxygen Transport to Tissue XXXIV, Springer New York, New York, NY, 2013: pp. 211–216. https://doi.org/10.1007/978-1-4614-4989-8_29.

[3]   D.J. Schweiger, Red cell distribution width in sickle cell anemia, Am J Med Technol. 47 (1981) 231–233.

[4]   R.O. Wallerstein, Laboratory Evaluation of Anemia, West J Medicine. 146 (1987) 443–451.

[5]   W.G. Thompson, T. Meola, M. Lipkin, M.L. Freedman, Red Cell Distribution Width, Mean Corpuscular Volume, and Transferrin Saturation in the Diagnosis of Iron Deficiency, JAMA Intern. Med. 148 (1988) 2128–2130.

[6]   M. Tonelli, F. Sacks, M. Arnold, L. Moye, B. Davis, M. Pfeffer, Relation between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People with Coronary Disease, Circulation. 117 (2008) 163–168. https://doi.org/10.1161/CIRCULATIONAHA.107.727545.

[7]   S.K. Zalawadiya, V. Veeranna, S.S. Panaich, L. Afonso, J.K. Ghali, Gender and Ethnic Differences in Red Cell Distribution Width and Its Association With Mortality Among Low Risk Healthy United State Adults, The American Journal of Cardiology. 109 (2012) 1664–1670. https://doi.org/10.1016/j.amjcard.2012.01.396.

[8]   B.F. Makhoul, A. Khourieh, M. Kaplan, F. Bahouth, D. Aronson, Z.S. Azzam, Relation between changes in red cell distribution width and clinical outcomes in acute

decompensated heart failure, Int J Cardiol. 167 (2013) 1412–1416.

https://doi.org/10.1016/j.ijcard.2012.04.065.

[9]   N. Li, H. Zhou, Q. Tang, Red Blood Cell Distribution Width: A Novel Predictive Indicator for

Cardiovascular and Cerebrovascular Diseases, Disease Markers. 2017 (2017) 1–23.

https://doi.org/10.1155/2017/7089493.

[10] N. Shah, M. Pahuja, S. Pant, A. Handa, V. Agarwal, N. Patel, R. Dusaj, Red cell distribution

width and risk of cardiovascular mortality: Insights from National Health and Nutrition

Examination Survey (NHANES)-III, Int. J. Cardiol. 232 (2017) 105–110.

https://doi.org/10.1016/j.ijcard.2017.01.045.

[11] S. Huang, Q. Zhou, N. Guo, Z. Zhang, L. Luo, Y. Luo, Z. Qin, L. Ge, Association between red

blood cell distribution width and in-hospital mortality in acute myocardial infarction,

Medicine. 100 (2021) e25404. https://doi.org/10.1097/MD.0000000000025404.

[12] D. Lazzeroni, L. Moderato, P.L. Marazzi, C. Pellegrino, E. Musiari, P. Castiglioni, U.

Camaiora, M. Bini, S. Geroldi, L. Brambilla, V. Brambilla, P. Coruzzi, Red blood cell

distribution width as a novel prognostic marker after myocardial revascularization or

cardiac valve surgery, Sci Rep. 11 (2021) 7889. https://doi.org/10.1038/s41598-021-

87075-4.

[13] B.H. Foy, J.C.T. Carlson, E. Reinertsen, R. Padros I. Valls, R. Pallares Lopez, E. Palanques-

Tost, C. Mow, M.B. Westover, A.D. Aguirre, J.M. Higgins, Association of Red Blood Cell

Distribution Width with Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection,

JAMA Network Open. 3 (2020) e2022058.

https://doi.org/10.1001/jamanetworkopen.2020.22058.

[14] J.L. Rapp, D. Tremblay, N. Alpert, W. Lieberman-Cribbin, J. Mascarenhas, E. Taioli, S.

Ghaffari, Red cell distribution width is associated with mortality in non-anemic patients

with COVID-19, J Med Virol. (2021) jmv.27011. https://doi.org/10.1002/jmv.27011.

[15] Z. Wang, Y.-W. Lin, X. Wei, F. Li, X.-L. Liao, H. Yuan, D. Huang, T. Qin, H. Geng, S. Wang,

Predictive Value of Prognostic Nutritional Index on COVID-19 Severity, Front. Nutr. 7

(2021) 582736. https://doi.org/10.3389/fnut.2020.582736.

[16] E. Dalbaşı, Ö.L. Akgül, Are average platelet volume, red cell distribution width and platelet

distribution width guiding markers for acute appendicitis treatment options?, Int J Clin

Pract. (2021). https://doi.org/10.1111/ijcp.14232.

[17] Y. Li, Y. She, L. Fu, R. Zhou, W. Xiang, L. Luo, Association Between Red Cell Distribution

Width and Hospital Mortality in Patients with Sepsis, J Int Med Res. 49 (2021)

030006052110042. https://doi.org/10.1177/03000605211004221.

[18] H. Go, H. Ohto, K.E. Nollet, K. Sato, H. Ichikawa, Y. Kume, Y. Kanai, H. Maeda, N.

Kashiwabara, K. Ogasawara, M. Sato, K. Hashimoto, M. Hosoya, Red cell distribution width

as a predictor for bronchopulmonary dysplasia in premature infants, Sci Rep. 11 (2021)

7221. https://doi.org/10.1038/s41598-021-86752-8.

[19] Y. Koma, A. Onishi, H. Matsuoka, N. Oda, N. Yokota, Y. Matsumoto, M. Koyama, N. Okada,

N. Nakashima, D. Masuya, H. Yoshimatsu, Y. Suzuki, Increased Red Blood Cell Distribution

Width Associates with Cancer Stage and Prognosis in Patients with Lung Cancer, PLoS ONE.

8 (2013) e80240. https://doi.org/10.1371/journal.pone.0080240.

[20] Q. Chen, R. Mao, J. Zhao, X. Bi, Z. Li, Z. Huang, Y. Zhang, J. Zhou, H. Zhao, J. Cai,

Nomograms incorporating preoperative RDW level for the prediction of postoperative

complications and survival in colorectal liver metastases after resection, Ann Palliat Med.

10 (2021) 4143–4158. https://doi.org/10.21037/apm-20-2418.

[21] T. Dingjan, A.H. Futerman, The fine-tuning of cell membrane lipid bilayers accentuates

their compositional complexity, BioEssays. (2021) 1–15.

https://doi.org/10.1002/bies.202100021.

[22] W.S. Harris, C. von Schacky, The Omega-3 Index: a new risk factor for death from coronary

heart disease?, Prev. Med. 39 (2004) 212–220.

https://doi.org/10.1016/j.ypmed.2004.02.030.

[23] H.M. Vidgren, J.J. Agren, U. Schwab, T. Rissanen, O. Hänninen, M.I. Uusitupa,

Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes

and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-

rich oil among healthy young men, Lipids. 32 (1997) 697–705.

[24] M.R. Flock, A.C. Skulas-Ray, W.S. Harris, T.D. Etherton, J.A. Fleming, P.M. Kris-Etherton,

Determinants of erythrocyte omega-3 fatty acid content in response to fish oil

supplementation: A dose–response randomized controlled trial, J. Am. Heart Assoc. 2

(2013) e000513. https://doi.org/10.1161/JAHA.113.000513.

[25] T. Terano, A. Hirai, T. Hamazaki, S. Kobayashi, T. Fujita, Y. Tamura, A. Kumagai, Effect of

oral administration of highly purified eicosapentaenoic acid on platelet function, blood

viscosity and red cell deformability in healthy human subjects, Atherosclerosis. 46 (1983)

321–331.

[26] I.J. Cartwright, A.G. Pockley, J.H. Galloway, M. Greaves, F.E. Preston, The effects of dietary

omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids,

326 erythrocyte deformabilit and blood viscosity in healthy volunteers, Atherosclerosis. 55

327 (1985) 267–281.

328 [27] R. Bach, U. Schmidt, F. Jung, H. Kiesewetter, B. Hennen, E. Wenzel, H. Schieffer, L. Bette, S.

329 Heyden, Effects of Fish Oil Capsules in Two Dosages on Blood Pressure, Platelet Functions,

330 Haemorheological and Clinical Chemistry Parameters in Apparently Healthy Subjects, Ann

331 Nutr Metab. 33 (1989) 359–367. https://doi.org/10.1159/000177559.

332 [28] E. Hessel, J.J. Agren, M. Paulitschke, O. Hanninen, A. Hanninen, D. Lerche, Freshwater fish

333 diet affects lipid composition, deformability and aggregation properties of erythrocytes,

334 Atherosclerosis. 82 (1990) 37–42.

335 [29] R.E. Walker, K.H. Jackson, N.L. Tintle, G.C. Shearer, A. Bernasconi, S. Masson, R. Latini, B.

336 Heydari, R.Y. Kwong, M. Flock, P.M. Kris-Etherton, A. Hedengran, R.M. Carney, A. Skulas-

337 Ray, S.S. Gidding, A. Dewell, C.D. Gardner, S.M. Grenon, B. Sarter, J.W. Newman, T.L.

338 Pedersen, M.K. Larson, W.S. Harris, Predicting the effects of supplemental EPA and DHA

339 on the omega-3 index, Am. J. Clin. Nutr. 110 (2019) 1034–1040.

340 https://doi.org/10.1093/ajcn/nqz161.

341 [30] W.S. Harris, N.L. Tintle, F. Imamura, F. Qian, A.V. Ardisson Korat, M. Marklund, L. Djoussé,

342 J.K. Bassett, P.-H. Carmichael, Y.-Y. Chen, Y. Hirakawa, L.K. Kupers, M. Lankinen, R.A.

343 Murphy, C. Samieri, M.K. Senn, P. Shi, J.K. Virtanen, I.A. Brouwer, K.-L. Chien, G.

344 Eiriksdottir, N.G. Forouhi, J.M. Geleijnse, G.G. Giles, V. Gudnason, C. Helmer, A. Hodge, R.

345 Jackson, K.-T. Khaw, M. Laakso, H. Lai, D. Laurin, J. Lindsay, R. Micha, J. Mursu, T.

346 Ninomiya, W. Post, B.M. Psaty, U. Riserus, J.G. Robinson, A.H. Shadyab, L. Snetselaar, A.

347 Sala-Vila, Y. Sun, L.M. Steffen, M.Y. Tsai, N.J. Wareham, A.C. Wood, J.H.Y. Wu, F. Hu, Q.

Sun, D.S. Siscovick, R.N. Lemaitre, D. Mozaffarian, F. The Fatty Acids and Outcomes

Research Consortium, Blood n-3 fatty acid levels and total and cause-specific mortality

from 17 prospective studies, Nature Commun. 12 (2021) 1–9.

https://doi.org/10.1038/s41467-021-22370-2.

[31] C. Fava, F. Cattazzo, Z.-D. Hu, G. Lippi, M. Montagnana, The role of red blood cell

distribution width (RDW) in cardiovascular risk assessment: useful or hype?, Ann. Transl.

Med. 7 (2019) 581–581. https://doi.org/10.21037/atm.2019.09.58.

[32] P.M. Moriarty, P.G. Steg, L.K. Gorby, A.M. Zeiher, H.D. White, T. Sourdille, M.T. Roe, M.J.

Louie, J.W. Jukema, R.A. Harrington, S.G. Goodman, R. Diaz, V.A. Bittner, D.L. Bhatt, M.

Szarek, Q.H. Li, G.G. Schwartz, Relation of Red Blood Cell Distribution Width to Risk of

Major Adverse Cardiovascular Events, Death, and Effect of Alirocumab After Acute

Coronary Syndrome, in: American Heart Association, American Heart Association,

Phildadelphia, PA, 2019: p. 1.

[33] J. Lappegård, T. Ellingsen, K. Hindberg, E. Mathiesen, I. Njølstad, T. Wilsgaard, M.-L.

Løchen, S. Brækkan, J.-B. Hansen, Impact of Chronic Inflammation, Assessed by hs-CRP, on

the Association between Red Cell Distribution Width and Arterial Cardiovascular Disease:

The Tromsø Study, TH Open. 02 (2018) e182–e189. https://doi.org/10.1055/s-0038-

1651523.

[34] M.A. Zimmerman, Diagnostic Implications of C-Reactive Protein, Arch Surg. 138 (2003)

220. https://doi.org/10.1001/archsurg.138.2.220.

[35] A. Villaseñor, S.W. Flatt, C. Marinac, L. Natarajan, J.P. Pierce, R.E. Patterson, Postdiagnosis

C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study, Cancer

Epidemiol Biomarkers Prev. 23 (2014) 189–199. https://doi.org/10.1158/1055-9965.EPI-

13-0852.

[36] WHO, C-reactive protein concentrations as a marker of inflammation or infection for

interpreting biomarkers of micronutrient status., World Health Organization, Geneva,

Switzerland, 2014.

http://apps.who.int/iris/bitstream/10665/133708/1/WHO_NMH_NHD_EPG_14.7_eng.pdf

?ua=1.

[37] M.L. Knight, The Application of High-Sensitivity C-Reactive Protein in Clinical Practice: A

2015 Update, US Pharmacist. 40 (2015) 50–53.

[38] S. Jafarnejad, V. Boccardi, B. Hosseini, M. Taghizadeh, Z. Hamedifard, A Meta-analysis of

Randomized Control Trials: The Impact of Vitamin C Supplementation on Serum CRP and

Serum hs-CRP Concentrations, (2018).

https://doi.org/10.2174/1381612824666181017101810.

[39] T.C. Evans, D. Jehle, The red blood cell distribution width, J. Emerg. Med. 9 (1991) 71–74.

https://doi.org/10.1016/0736-4679(91)90592-4.

[40] M.D. Cappellini, I. Motta, Anemia in Clinical Practice—Definition and Classification: Does

Hemoglobin Change With Aging?, Sem. Hematol. 52 (2015) 261–269.

https://doi.org/10.1053/j.seminhematol.2015.07.006.

[41] T.D. Dayspring, S.A. Varvel, L. Ghaedi, D.L. Thiselton, J. Bruton, J.P. McConnell, Biomarkers

of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718

patients, Journal of Clinical Lipidology. 9 (2015) 807–816.

https://doi.org/10.1016/j.jacl.2015.08.003.

[42] W.S. Harris, J.V. Pottala, R.S. Vasan, M.G. Larson, S.J. Robins, Changes in erythrocyte

membrane trans and marine fatty acids between 1999 and 2006 in older Americans, J.

Nutr. 142 (2012) 1297–1303. https://doi.org/10.3945/jn.112.158295.

[43] T. Nemkov, J.A. Reisz, Y. Xia, J.C. Zimring, A. D'Alessandro, Red blood cells as an organ?

How deep omics characterization of the most abundant cell in the human body highlights

other systemic metabolic functions beyond oxygen transport, Expert Review of

Proteomics. 15 (2018) 855–864. https://doi.org/10.1080/14789450.2018.1531710.

[44] R. Huisjes, A. Bogdanova, W.W. van Solinge, R.M. Schiffelers, L. Kaestner, R. van Wijk,

Squeezing for Life – Properties of Red Blood Cell Deformability, Front. Physiol. 9 (2018)

656. https://doi.org/10.3389/fphys.2018.00656.

[45] P.L. Else, A.J. Hulbert, Membranes as metabolic pacemakers, Clin Exp Pharmacol Physiol.

30 (2003) 559–564. https://doi.org/10.1046/j.1440-1681.2003.03883.x.

[46] T.R. Witte, A.J. Salazar, O.F. Ballester, W.E. Hardman, RBC and WBC fatty acid composition

following consumption of an omega 3 supplement: Lessons for future clinical trials, Lipids

Health Dis. 9 (2010) 31. https://doi.org/10.1186/1476-511X-9-31.

[47] U. Radzikowska, A.O. Rinaldi, Z. Çelebi Sözener, D. Karaguzel, M. Wojcik, K. Cypryk, M.

Akdis, C.A. Akdis, M. Sokolowska, The Influence of Dietary Fatty Acids on Immune

Responses, Nutrients. 11 (2019) 2990. https://doi.org/10.3390/nu11122990.

[48] T. Kamada, T. Yamashita, Y. Baba, M. Kai, S. Setoyama, Y. Chuman, S. Otsuji, Dietary

Sardine Oil Increases Erythrocyte Membrane Fluidity in Diabetic Patients, Diabetes. 35

(1986) 604–611.

[49] H.F. Turk, R.S. Chapkin, Membrane lipid raft organization is uniquely modified by n-3

polyunsaturated fatty acids, PLEFA. 88 (2013) 43–47.

[50] K. Gawrisch, N.V. Eldho, L.L. Holte, The structure of DHA in phospholipid membranes,

Lipids. 38 (2003) 445–452.

[51] E. Tajima, S. Abe, R. Watanabe, Y. Koyabu, F. Saito, H. Kaneda, M. Sakuma, S. Toyoda, T.

Inoue, Effects of purified eicosapentaenoic acid on red blood cell distribution width and

vascular endothelial function in patients with coronary artery disease, Vasc Fail. 1 (2017)

15–21. https://doi.org/10.30548/vascfail.1.1_15.

[52] J. Kim, H. Lee, S. Shin, Advances in the measurement of red blood cell deformability: A

brief review, J. Cell Biotechnol. 1 (2015) 63–79. https://doi.org/10.3233/JCB-15007.

[53] G.L. Salvagno, F. Sanchis-Gomar, A. Picanza, G. Lippi, Red blood cell distribution width: A

simple parameter with multiple clinical applications, Critical Reviews in Clinical Laboratory

Sciences. 52 (2015) 86–105. https://doi.org/10.3109/10408363.2014.992064.

[54] I. Liguori, G. Russo, F. Curcio, G. Bulli, L. Aran, D. Della-Morte, G. Gargiulo, G. Testa, F.

Cacciatore, D. Bonaduce, P. Abete, Oxidative stress, aging, and diseases, Clin. Intervent.

Aging. Volume 13 (2018) 757–772. https://doi.org/10.2147/CIA.S158513.

[55] M. Minetti, L. Agati, W. Malorni, The microenvironment can shift erythrocytes from a

friendly to a harmful behavior: Pathogenetic implications for vascular diseases,

Cardiovascular Research. 75 (2007) 21–28.

https://doi.org/10.1016/j.cardiores.2007.03.007.

[56] J. Heshmati, M. Morvaridzadeh, S. Maroufizadeh, A. Akbari, M. Yavari, A. Amirinejad, A.

Maleki-Hajiagha, M. Sepidarkish, Omega-3 fatty acids supplementation and oxidative

stress parameters: A systematic review and meta-analysis of clinical trials,

Pharmacological Research. 149 (2019) 104462.

https://doi.org/10.1016/j.phrs.2019.104462.

[57] S. Ranka, S. Lahan, T. Dalia, A. Tripathi, A. Goyal, J. Sreenivasan, S. Taduru, M. Muhammed,

P. Moriarty, Association Between Red Cell Distribution Width and Cardiovascular

Outcomes – Systematic Review and Meta-Analysis, MRAJ. 9 (2021).

https://doi.org/10.18103/mra.v9i7.2468.

[58] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms

and clinical relevance, Bioch. Biophys. Acta: Mol Cell Biol Lipids. 1851 (2015) 469–484.

https://doi.org/10.1016/j.bbalip.2014.08.010.

[59] P.C. Calder, Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving

mediators: Concentrations in humans and the effects of age, sex, disease and increased

omega-3 fatty acid intake, Biochimie. 178 (2020) 105–123.

https://doi.org/10.1016/j.biochi.2020.08.015.

[60] J.D. Fontes, F. Rahman, S. Lacey, M.G. Larson, R.S. Vasan, E.J. Benjamin, W.S. Harris, S.J.

Robins, Red blood cell fatty acids and biomarkers of inflammation: A cross-sectional study

in a community-based cohort, Atherosclerosis. 240 (2015) 431–436.

https://doi.org/10.1016/j.atherosclerosis.2015.03.043.

[61] K. Li, T. Huang, J. Zheng, K. Wu, D. Li, Effect of Marine-Derived n-3 Polyunsaturated Fatty

Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α: A Meta-Analysis,

PLoS ONE. 9 (2014) e88103. https://doi.org/10.1371/journal.pone.0088103.

[62] US Dept Health & Human Services, Nutrient Assessment for DRI Review, Nutient

457   Assessment for DRI Review. (2014). https://health.gov/our-work/food-nutrition/dietary-

458   reference-intakes-dris/nutrient-assessment-dri-review (accessed October 20, 2020).

459   [63] M.I. McBurney, J.B. Blumberg, R.B. Costello, M. Eggersdorfer, J.W.E. Jr, W.S. Harris, E.J.

460   Johnson, S.H. Mitmesser, R.C. Post, D. Rai, L.J. Schurgers, Beyond Nutrient Deficiency—

461   Opportunities to Improve Nutritional Status and Promote Health Modernizing DRIs and

462   Supplementation Recommendations, Nutrients. 13 (2021) 1–25.

463   https://doi.org/10.3390/nu13061844.

464   [64] P.M. Kris-Etherton, J.A. Grieger, T.D. Etherton, Dietary Reference Intakes for DHA and EPA,

465   PLEFA. 81 (2009) 99–104. https://doi.org/10.1016/j.plefa.2009.05.011.

466   [65] W.S. Harris, D. Mozaffarian, M. Lefevre, C.D. Toner, J. Colombo, S.C. Cunnane, J.M. Holden,

467   D.M. Klurfeld, M.C. Morris, J. Whelan, Towards establishing dietary reference intakes for

468   eicosapentaenoic and docosahexaenoic acids, J. Nutr. 139 (2009) 804S-819S.

469   https://doi.org/10.3945/jn.108.101329.

470   [66] A. Daak, A. Rabinowicz, K. Ghebremeskel, Omega-3 fatty acids are a potential therapy for

471   patients with sickle cell disease, Nat Rev Dis Primers. 4 (2018) 15.

472   https://doi.org/10.1038/s41572-018-0012-9.

473   [67] A.A. Daak, M.A. Lopez-Toledano, M.M. Heeney, Biochemical and therapeutic effects of

474   Omega-3 fatty acids in sickle cell disease, Complement. Therap. Med. 52 (2020) 102482.

475   https://doi.org/10.1016/j.ctim.2020.102482.

476   [68] M. Takahashi, M. Myojo, A. Watanabe, A. Kiyosue, K. Kimura, J. Ando, Y. Hirata, I. Komuro,

477   Effect of purified eicosapentaenoic acid on red cell distribution width in patients with

ischemic heart disease, Heart Vessels. 30 (2015) 587–594.

https://doi.org/10.1007/s00380-014-0526-3.

[69] L.T. Meital, M.T. Windsor, R.M.L. Ramirez Jewell, P. Young, K. Schulze, R. Magee, J.

O'Donnell, P. Jha, M. Perissiou, J. Golledge, T.G. Bailey, P. Brooks, C.D. Askew, F.D. Russell,

n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized

controlled trial, J. Lipid Res. 60 (2019) 1154–1163. https://doi.org/10.1194/jlr.P093013.

[70] E. Wolin, J. White, J.V. Pottala, M. Sasinowski, T. Dall, T.D. Dayspring, J.P. McConnell, D.M.

Hoefner, S.A. Varvel, D.L. Thiselton, G.R. Warnick, W.S. Harris, Comparison of

cardiometabolic risk biomarkers from a national clinical laboratory with the US adult

population, J. Clin. Lipid. 9 (2015) 817–823. https://doi.org/10.1016/j.jacl.2015.07.014.

[71] R.A. Murphy, P.P. Devarshi, S. Ekimura, K. Marshall, S. Hazels Mitmesser, Long-chain

omega-3 fatty acid serum concentrations across life stages in the USA: an analysis of

NHANES 2011–2012, BMJ Open. 11 (2021) e043301. https://doi.org/10.1136/bmjopen-

2020-043301.

[72] V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red

cell distribution width and high sensitivity C-reactive protein for coronary heart disease

mortality prediction in multi-ethnic population: Findings from the 1999–2004 NHANES, Int.

J. Cardiol. 168 (2013) 5156–5161. https://doi.org/10.1016/j.ijcard.2013.07.109.

[73] N. Shah, M. Pahuja, S. Pant, A. Handa, V. Agarwal, N. Patel, R. Dusaj, Red cell distribution

width and risk of cardiovascular mortality: Insights from National Health and Nutrition

Examination Survey (NHANES)-III, International Journal of Cardiology. 232 (2017) 105–110.

https://doi.org/10.1016/j.ijcard.2017.01.045.

[74] W.S. Harris, The Omega-3 Index: Clinical Utility for Therapeutic Intervention, Curr Cardiol

Rep. 12 (2010) 503–508. https://doi.org/10.1007/s11886-010-0141-6.

Variable[1]	All (n=25,485)	Males (n=12,811)	Females (n=12,674)	Male vs Female Adjusted[2] p-value
O3I (%)	4.99±1.83	4.90±1.81	5.07±1.85	0.0003
RDW (%)	13.60±0.90	13.60±0.83	13.69±0.96	0.0002
MCV (fL)	92.45±4.27	92.33±4.25	92.57±4.28	0.36
Hb (g/dL)	14.40±1.21	15.14±1.03	13.65±0.88	<0.00001
CRP (mg/L)	1.23±0.77	1.21±0.75	1.25±0.78	<0.00001
BMI (kg/m²)	27.7±5.3	28.8±4.8	25.6±5.5	<0.00001
Age (years)	54.3±14.8	54.1±14.4	54.4±15.2	0.077

Table 1. Characteristics of the study population. Mean±SD.

[1]O3I, Omega-3 index; RDW, red blood cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; CRP, high-sensitivity C-reactive protein; BMI, body mass index.

[2]Models were adjusted for age, BMI, and CRP (except when the model was predicting these variables).

Table 2. Characteristics of subjects by sex and omega-3 index (O3I) classification. (Mean±SD)					
Variable[1]	Female[2] (n=12,674)		Male[3] (n=12,811)		Sex*O3I Interaction
	O3I ≤5.6% (n=8,475)	O3I >5.6% (n=4,199)	O3I ≤5.6% (n=9,037)	O3I >5.6% (n=3,774)	Adjusted[4] p-value
O3I (%)	3.99±0.86	7.26±1.32	3.94±0.86	7.21±1.33	0.47
RDW	13.64±0.98	13.52±0.90	13.60±0.84	13.59±0.80	0.00066
CRP (mg/L)	1.31±0.79	1.13±0.75	1.26±0.76	1.09±0.71	0.03
BMI (kg/m²)	27.2±5.7	25.3±4.9	29.1±4.9	28.1±4.5	<0.00001
Age (years)	52.6±15.6	57.9±13.5	52.6±14.6	57.9±13.3	0.90

[1] O3I, omega-3 index; RDW, red blood cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; CRP, high-sensitivity C-reactive protein; BMI, body mass index.

[2] All variables between O3I categories (≤5.6% vs >5.6%) for females were p<0.0001 in both adjusted and unadjusted analyses.

[3] All variables between O3I categories (≤5.6% vs >5.6%) for males were p<0.0001 in both adjusted and unadjusted analyses, except for unadjusted difference in RDW by O3I category, p=0.31.

[4] Model further adjusted for age, BMI, and CRP.

Figure 1. Analytical sample flow chart. RDW, red blood cell distribution width; O3I, omega-3

index; MCV, mean corpuscular cell volume; Hb, hemoglobin.

Figure 2. The unadjusted (A) and adjusted for age, sex, BMI and CRP (B) relationship between

the red blood cell distribution width (RDW) and omega-3 index (O3I) in 25,485 adults without

inflammation or anemia. (Predicted means and 95% confidence bands).

Figure 3. The unadjusted (A) and adjusted for age, BMI, and CRP (B) relationships between the

red blood distribution width (RDW) and omega-3 index (O3I) in 12,811 males (A) and 12,674

females (B) without inflammation or anemia. (Predicted means and 95% confidence bands).